Buscar
Mostrando ítems 1-10 de 11
Vogt-Koyanagi-Harada disease: the stepby-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review
(2022)
Background: Appraisals of Vogt-Koyanagi-Harada disease (VKH) have become progressively more complete, since its first description in 1906. The availability of new investigational methods has improved our knowledge of the ...
Initial-onset acute and chronic recurrent stages are two distinctive courses of VogtKoyanagi-Harada disease
(Springer, 2020)
Purpose: To describe distinctive stages of Vogt-Koyanagi-Harada (VKH) disease: initial-onset acute versus chronic
recurrent disease.
Methods: A comprehensive literature review regarding stages and clinical presentations ...
Initial-onset acute and chronic recurrent stages are two distinctive courses of VogtKoyanagi-Harada disease
(2020)
Purpose: To describe distinctive stages of Vogt-Koyanagi-Harada (VKH) disease: initial-onset acute versus chronic recurrent disease.
Methods: A comprehensive literature review regarding stages and clinical presentations ...
miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease
(2021)
miRNAs, one of the members of the noncoding RNA family, are regulators of gene expression in inflammatory and autoimmune diseases. Changes in miRNA pool expression have been associated with differentiation of CD4+ T cells ...
miRNA landscape in pathogenesis and treatment of vogt–koyanagi–harada disease
(Frontiers Media, 2021)
miRNAs, one of the members of the noncoding RNA family, are regulators of gene expression in inflammatory and autoimmune diseases. Changes in miRNA pool expression have been associated with differentiation of CD4(+) T cells ...
Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt–Koyanagi–Harada disease: an updated review
(2022)
Vogt-Koyanagi-Harada (VKH) disease is a primary autoimmune stromal choroiditis. This review aimed to provide a novel perspective of the disease. We took into account recent developments in the understanding of the disease ...
Adalimumab, therapeutic alternative in the Vogt Koyanagi Harada syndrome refractory to infliximab: case reportAdalimumab como alternativa terapéutica en el síndrome de Vogt Koyanagi Harada refractario al infliximab: reporte de caso
(Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana, 2016)
Evaluation of the glucocorticoid receptor as a biomarker of treatment response in Vogt-Koyanagi-Harada disease
(Association for Research in Vision and Ophthalmology Inc., 2017)
© 2017 The Authors. PURPOSE. This study is aimed to investigate the role of glucocorticoid receptor (GR) isoforms in peripheral blood mononuclear cells (PBMC) as biomarkers of glucocorticoid (GC) resistance and to validate ...
New insights into Vogt-Koyanagi-Harada disease
(Conselho Brasileiro de Oftalmologia, 2009)
Vogt-Koyanagi-Harada disease (VKH), a well-established multiorgan disorder affecting pigmented structures, is an autoimmune disorder of melanocyte proteins in genetically susceptible individuals. Several clinical and ...
Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease
(Wiley-Blackwell, 2015)
Purpose: To evaluate clinical outcomes of first-line immunomodulatory therapy (IMT) and prednisone alone or late IMT in Vogt-Koyanagi-Harada disease.
Methods: Retrospective cohort study of 152 patients with ...